GKOS
USDGlaukos Corporation Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$85.860
Kõrge
$88.290
Madal
$85.235
Maht
0.50M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
4.9B
Tööstusharu
Meditsiiniseadmed
Riik
United States
Kauplemisstatistika
Keskmine maht
1.05M
Börs
NYQ
Valuuta
USD
52 nädala vahemik
Seotud uudised
Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its
JP Morgan Maintains Overweight on Glaukos, Raises Price Target to $120
JP Morgan analyst Allen Gong maintains Glaukos with a Overweight and raises the price target from $110 to $120.
Citigroup Maintains Buy on Glaukos, Raises Price Target to $113
Citigroup analyst Joanne Wuensch maintains Glaukos with a Buy and raises the price target from $110 to $113.
Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $122
Wells Fargo analyst Larry Biegelsen maintains Glaukos with a Overweight and raises the price target from $120 to $122.
Needham Maintains Buy on Glaukos, Raises Price Target to $117
Needham analyst David Saxon maintains Glaukos with a Buy and raises the price target from $115 to $117.
BTIG Maintains Buy on Glaukos, Raises Price Target to $116
BTIG analyst Ryan Zimmerman maintains Glaukos with a Buy and raises the price target from $104 to $116.
Glaukos Announces Third Quarter 2025 Financial Results
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.